[go: up one dir, main page]

BR0001602A - Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos - Google Patents

Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos

Info

Publication number
BR0001602A
BR0001602A BR0001602-0A BR0001602A BR0001602A BR 0001602 A BR0001602 A BR 0001602A BR 0001602 A BR0001602 A BR 0001602A BR 0001602 A BR0001602 A BR 0001602A
Authority
BR
Brazil
Prior art keywords
heteroarylalkyl
group
optionally substituted
pharmaceutical compositions
compositions containing
Prior art date
Application number
BR0001602-0A
Other languages
English (en)
Inventor
Jean-Luc Fauchere
Jean-Claude Ortuno
Jacques Duhault
Jean Albert Boutin
Nigel Levens
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of BR0001602A publication Critical patent/BR0001602A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DE AMINOTRIAZOL, PROCESSO PARA A PREPARAçãO DOS MESMOS E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS"<D>. O composto da fórmula (I): em que: n é 0 ou 1, W representa -CO- ou S(O)~ q~ e q é 0, 1 ou 2, G representa um grupo G~ 1~, G~ 2~, G~ 3~ ou G~ 4~ como definidos na descrição, Z representa um grupo alquil, ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente, A representa um grupamento selecionado de -A~ 2~-, -A~ 1~<sym>A~ 2~-, -A~ 2~-A~ 1~- e -A~ 1~-A~ 2~-A~ 1~- em que A~ 1~ é um grupo alquileno e A~ 2~ representa um grupo fenileno, cicloalquileno, naftileno ou heteroarileno, cada um substituído opcionalmente, R representa um átomo de hidrogênio, um grupo alquil ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente, R~ 1~ representa um grupo alquil ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente.
BR0001602-0A 1999-04-15 2000-04-13 Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos BR0001602A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904721A FR2792314B1 (fr) 1999-04-15 1999-04-15 Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR0001602A true BR0001602A (pt) 2001-08-21

Family

ID=9544433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0001602-0A BR0001602A (pt) 1999-04-15 2000-04-13 Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos

Country Status (19)

Country Link
US (2) US6245916B1 (pt)
EP (1) EP1044970B1 (pt)
JP (1) JP2000309579A (pt)
KR (1) KR20010020732A (pt)
CN (1) CN1145616C (pt)
AT (1) ATE231133T1 (pt)
BR (1) BR0001602A (pt)
CA (1) CA2305940A1 (pt)
DE (1) DE60001190T2 (pt)
DK (1) DK1044970T3 (pt)
EA (1) EA003023B1 (pt)
ES (1) ES2190396T3 (pt)
FR (1) FR2792314B1 (pt)
HU (1) HUP0001562A3 (pt)
NO (1) NO20001964L (pt)
NZ (1) NZ504023A (pt)
PL (1) PL339690A1 (pt)
SI (1) SI1044970T1 (pt)
ZA (1) ZA200001908B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
JP2005508841A (ja) * 2001-03-29 2005-04-07 スミスクライン・ビーチャム・コーポレイション 化合物および方法
MXPA02010231A (es) 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1799656A4 (en) * 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
JP4958785B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
MX2007003330A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
MX2007003329A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
CN101084211A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
WO2006034441A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580844A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2286837A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
EP2540296A1 (en) * 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
JP5685364B2 (ja) * 2006-01-17 2015-03-18 スティーフェル・ラボラトリーズ・インコーポレーテッド トリアゾール化合物による炎症性疾患の処置
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
MX2010004177A (es) 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.
BRPI0722276A2 (pt) * 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
ES2442932T3 (es) 2008-03-19 2014-02-14 Janssen Pharmaceutica N.V. 1,2,4-Triazoles trisustituidos como moduladores de receptores nicotínicos de acetilcolina
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CL2009001125A1 (es) * 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8775245B2 (en) 2010-02-11 2014-07-08 News America Marketing Properties, Llc Secure coupon distribution
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2013003633A (es) * 2010-10-01 2013-04-24 Taisho Pharmaceutical Co Ltd Derivado de 1, 2, 4-triazolona.
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
BR112021009589A2 (pt) 2018-11-20 2021-08-17 Tes Pharma S.R.L. inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0891325T3 (da) * 1996-03-29 2002-05-21 Searle & Co Para-substituerede phenylpropansyrederivater som integrinantagonister
DE69729315T2 (de) * 1996-12-16 2005-06-23 Banyu Pharmaceutical Co., Ltd. Aminopyrazolderivate
CO5011105A1 (es) * 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion

Also Published As

Publication number Publication date
CN1145616C (zh) 2004-04-14
FR2792314A1 (fr) 2000-10-20
EA003023B1 (ru) 2002-12-26
ES2190396T3 (es) 2003-08-01
CN1272493A (zh) 2000-11-08
US6596749B2 (en) 2003-07-22
DK1044970T3 (da) 2003-04-22
CA2305940A1 (fr) 2000-10-15
KR20010020732A (ko) 2001-03-15
FR2792314B1 (fr) 2001-06-01
PL339690A1 (en) 2000-10-23
JP2000309579A (ja) 2000-11-07
HUP0001562A3 (en) 2003-05-28
EP1044970A1 (fr) 2000-10-18
NO20001964D0 (no) 2000-04-14
HUP0001562A2 (hu) 2001-04-28
DE60001190T2 (de) 2003-10-09
NZ504023A (en) 2000-10-27
SI1044970T1 (en) 2003-06-30
DE60001190D1 (de) 2003-02-20
ZA200001908B (en) 2000-10-31
US6245916B1 (en) 2001-06-12
EA200000327A2 (ru) 2000-10-30
EP1044970B1 (fr) 2003-01-15
ATE231133T1 (de) 2003-02-15
HU0001562D0 (en) 2000-06-28
US20010018522A1 (en) 2001-08-30
NO20001964L (no) 2000-10-16

Similar Documents

Publication Publication Date Title
BR0001602A (pt) Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
BR9910474A (pt) Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
PT813546E (pt) Derivados de polissacarideos contendo ligacoes cruzadas por fotoquimica como suporte para a separacao cromatografica de enantiomeros
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
BR0112043A (pt) Ftalidas substituìdas, processo para sua preparação e composições farmacêuticas contendo-as
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
BR0004823A (pt) Compostos policìclicos de azaindol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0104471A (pt) Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BR9813217A (pt) Tetraciclos, processo para a produção dos mesmos e preparações farmacêuticas contendo estes compostos
BRPI0403028A (pt) Compostos heterocìclicos de oxima, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR9812752A (pt) Derivados de 8-azabiciclo [3.2.1] octano-3-metanamina enquanto ligandos dos receptores de dopamina d2 e d3 e de serotonina 5ht1a e 5ht2
BR9907497A (pt) Compostos de imidazolina, um processo para seu preparo e compostos farmacêuticos contendo os mesmos
BR9813712A (pt) Derivados de n-fenilamida e n-piridilamida, método para preparação dos mesmos e composições farmacêuticas contendo os mesmos
DE69230446D1 (de) (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
EP1424326A4 (en) CONDENSED POLYCYCLIC COMPOUNDS
MXPA04003200A (es) Nuevos compuestos de isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR9815081A (pt) Compostos tricìclicos, um processo para a sua preparação e composições farmacêuticas contendo-os
ATE8389T1 (de) Amino-alkoxy-pyrazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
BR0001628A (pt) Processo para a preparação de um composto aromático substituìdo por uma nitrila terciária
BR0100600A (pt) Compostos de ácido de aril ou heteroaril quinolinilfosfÈnico, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0002679A (pt) Compostos de carboxilato de 7-oxo-2,3,7,14, tetraidro-1h-benzo[b]-pirano[3,2-h]acridina, processo para a sua preparação e composições farmacêuticas contendo os mesmos
CA2165618A1 (fr) Nouveaux ethers d&#39;oximes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
PC Transfer

Free format text: LES LABORATOIRES SERVIER (FR)

FA10 Dismissal: dismissal - article 33 of industrial property law
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.